The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
(1S,2R,3aR,4S,6aR)-4-((2-amino-3-bromoquinolin-7-yl)methyl)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)octahydropentalene-1,6a-diol ID: ALA4846178
PubChem CID: 156705377
Max Phase: Preclinical
Molecular Formula: C24H25BrN6O2
Molecular Weight: 509.41
Molecule Type: Unknown
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: Nc1nc2cc(C[C@@H]3CC[C@@]4(O)[C@@H]3C[C@@H](n3ccc5c(N)ncnc53)[C@@H]4O)ccc2cc1Br
Standard InChI: InChI=1S/C24H25BrN6O2/c25-17-9-14-2-1-12(8-18(14)30-22(17)27)7-13-3-5-24(33)16(13)10-19(20(24)32)31-6-4-15-21(26)28-11-29-23(15)31/h1-2,4,6,8-9,11,13,16,19-20,32-33H,3,5,7,10H2,(H2,27,30)(H2,26,28,29)/t13-,16+,19+,20-,24+/m0/s1
Standard InChI Key: CUHBMWWZOQHSJP-CVXUCQRBSA-N
Molfile:
RDKit 2D
34 39 0 0 0 0 0 0 0 0999 V2000
7.5094 -18.7113 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
8.3191 -17.6645 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.5363 -17.8958 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.7803 -18.3422 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.2795 -18.9832 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.5843 -19.7353 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
9.3897 -19.8476 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.8893 -19.2018 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
9.5817 -18.4523 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.8417 -19.1685 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.0821 -17.8061 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
6.0759 -18.8963 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.5765 -19.5432 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.0375 -20.2181 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.8216 -19.9881 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.7945 -19.7679 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.7665 -20.5811 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.5312 -20.8589 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.4343 -20.9209 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
4.1503 -19.2651 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.3927 -19.5716 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.7497 -19.0660 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.9927 -19.3719 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.2824 -20.3767 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.5280 -20.6853 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.8823 -20.1802 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.1242 -20.4871 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.0105 -21.2987 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.6611 -21.8026 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.4167 -21.4930 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.5511 -22.6123 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.2535 -21.6066 0.0000 Br 0 0 0 0 0 0 0 0 0 0 0 0
7.4645 -20.4848 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
5.5718 -18.7252 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0
1 5 1 0
4 2 1 0
2 3 2 0
3 1 1 0
4 5 2 0
5 6 1 0
6 7 2 0
7 8 1 0
8 9 2 0
9 4 1 0
10 1 1 1
9 11 1 0
10 12 1 0
12 13 1 0
13 14 1 0
14 15 1 0
15 10 1 0
13 16 1 0
16 17 1 0
17 18 1 0
18 14 1 0
14 19 1 6
16 20 1 1
20 21 1 0
21 22 2 0
22 23 1 0
23 26 2 0
25 24 2 0
24 21 1 0
25 26 1 0
26 27 1 0
27 28 2 0
28 29 1 0
29 30 2 0
30 25 1 0
29 31 1 0
28 32 1 0
15 33 1 6
13 34 1 6
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 509.41Molecular Weight (Monoisotopic): 508.1222AlogP: 3.21#Rotatable Bonds: 3Polar Surface Area: 136.10Molecular Species: NEUTRALHBA: 8HBD: 4#RO5 Violations: 1HBA (Lipinski): 8HBD (Lipinski): 6#RO5 Violations (Lipinski): 2CX Acidic pKa: 13.14CX Basic pKa: 6.25CX LogP: 2.97CX LogD: 2.94Aromatic Rings: 4Heavy Atoms: 33QED Weighted: 0.33Np Likeness Score: 0.74
References 1. Quiroz RV, Reutershan MH, Schneider SE, Sloman D, Lacey BM, Swalm BM, Yeung CS, Gibeau C, Spellman DS, Rankic DA, Chen D, Witter D, Linn D, Munsell E, Feng G, Xu H, Hughes JME, Lim J, Saurí J, Geddes K, Wan M, Mansueto MS, Follmer NE, Fier PS, Siliphaivanh P, Daublain P, Palte RL, Hayes RP, Lee S, Kawamura S, Silverman S, Sanyal S, Henderson TJ, Ye Y, Gao Y, Nicholson B, Machacek MR.. (2021) The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer., 64 (7.0): [PMID:33755451 ] [10.1021/acs.jmedchem.0c02083 ]